IP Library Granted Patent US 9,156,986
Granted Patent B2
US 9,156,986 · App. 13/065,101 · Granted Oct 13, 2015

Multisignal labeling reagents and processes and uses therefor

Inventors: Jack Coleman (East Northport, NY); Elazar Rabbani (New York, NY); Jannis Stavrianopoulos (Bay Shore, NY); Praveen Pande (Holbrook, NY)
Assignee: Enzo Life Sciences, Inc.
C09B11/24C07D219/08C07D405/14C07D491/22C07H21/00C07H21/04C09B11/00C09B11/08C09B57/02C12Q1/68G01N33/533C12Q1/6818
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,156,986
App. No.
13/065,101
Granted
Oct 13, 2015
Kind
B2
Abstract

Provided are compounds comprising two DNA supramolecular binding molecules covalently joined by a linker group. Also provided are multisignal labeling reagents comprising (i) an oligomer of nucleotides or nucleotide analogs; (ii) a DNA supramolecular binding molecule noncovalently bound to the oligomer; and (iii) a first reactive group or a first partner of a first binding pair covalently bound to the oligomer. Additionally provided are methods of producing multisignal labeling reagents.

Claims (28)

1. A compound comprising two DNA supramolecular binding molecules covalently joined by a linker group, the compound further comprising a detectable label bound thereto selected from a fluorescent compound, a phosphorescent compound, a chemiluminescent compound, a chelating compound, a magnetic compound and an energy transfer compound, wherein the detectable label is not either of the two DNA supramolecular binding molecules, and wherein said supramolecular binding molecules are each independently selected from a minor groove binder, and a major groove binder.

2. The compound of claim 1 , wherein at least one of the DNA supramolecular binding molecules is a minor groove binder.

3. The compound of claim 2 , wherein the minor groove binder is a diacrylamidine, or a bis-benzimidazole.

4. The compound of claim 2 , wherein the minor groove binder is DAPI, berenil, pentamidine, distamycin A, or Hoechst 33258.

5. The compound of claim 1 , wherein at least one of the DNA supramolecular binding molecules is a major groove binder.

6. The compound of claim 5 , wherein the major groove binder is selected from a zinc finger, a leucine zipper and a helix-turn-helix motif.

7. A compound comprising two DNA supramolecular binding molecules covalently joined by a linker group, the compound further comprising a detectable label bound thereto selected from a fluorescent compound, a phosphorescent compound, a chemiluminescent compound, a chelating compound, a magnetic compound and an energy transfer compound, wherein the detectable label is not either of the two DNA supramolecular binding molecules, and wherein one of said DNA supramolecular binding molecules is selected from a minor groove binder, and a major groove binder, and the other DNA supramolecular binding molecule is an intercalator.

8. The compound of claim 7 , wherein the intercalator is selected from an acridine intercalator, a coumarin intercalator, a psoralen intercalator, a phenanthridine intercalator, a quinoxaline intercalator, an anthracycline intercalator, and a metallo-intercalator.

9. The compound of claim 8 , wherein the intercalator is selected from 9-aminoacridine, 7-hydroxy-4-methylcoumarin, 7-amino-4-methylcoumarin, 4-methyl-7-sulphato-methylcoumarin, 8[[[(diethylamino)methyl]propyl]oxy]psoralen, 5(N-piperadinyl)-8-methoxypsoralen, ethidium bromide, thiazole orange, 6-(-4′-carboxyphenyl)-3,8-diamine-5-methyl phenanthridinium chloride, doxorubicin, daunomycin, [Pt(tpy)(SCH 2 CH 2 OH)] + , and [Rh(phi)(Me 2 trien)] 3+ .

10. The compound of claim 1 or claim 7 , wherein the linker is flexible.

11. The compound of claim 1 or claim 7 , wherein the linker is an unsubstituted C 1 -C 20 straight-chain, branched or cyclic alkyl, alkenyl or alkynyl group, a substituted C 1 -C 20 straight-chain, branched or cyclic alkyl, alkenyl or alkynyl group wherein one or more C, CH or CH 2 groups are substituted with an O atom, N atom, S atom, NH group, CO group or OCO group, or an unsubstituted or substituted aromatic group.

12. The compound of claim 1 or claim 7 , wherein the linker is —(CH 2 ) 1-10 —NH—(CH 2 ) 1-10 —.

13. The compound of claim 1 or claim 7 , wherein the linker is —(CH 2 ) 1-5 —NH—(CH 2 ) 1-5 —.

14. The compound of claim 1 or claim 7 , wherein the linker is —(CH 2 ) 3 —NH—(CH 2 ) 4 —.

15. The compound of claim 1 or claim 7 wherein the detectable label is a fluorophore.

16. The compound of claim 15 , wherein the fluorophore is selected from a symmetric or asymmetric cyanine, a merocyanine, a styryl moiety, an oxazine, a xanthene, a coumarin or an iminocoumarin.

17. The compound of claim 16 , wherein the fluorophore is a xanthene.

18. The compound of claim 17 , wherein the xanthene is a rhodamine or rhodamine derivative.

19. The compound of claim 17 , wherein the xanthene is a rosamine or rosamine derivative.

20. The compound of claim 17 , wherein the xanthene is a rhodol or rhodol derivative.

21. The compound of claim 16 , wherein the fluorophore is a coumarin.

22. The compound of claim 21 , wherein the coumarin is an iminocoumarin.

23. The compound of claim 1 or claim 7 wherein the detectable label is a chemiluminescent or phosphorescent moiety.

24. The compound of claim 1 or claim 7 , wherein the detectable label is non-covalently bound to the compound via a binding pair.

25. The compound of claim 1 or claim 7 , wherein the detectable label is covalently bound to the compound.

26. The compound of claim 25 , wherein the detectable label is bound to the linker group.

27. The compound of claim 1 , further comprising a third DNA supramolecular binding molecule that is an intercalator covalently joined by a linker group that is linked to the linker group that joins the two DNA supramolecular binding molecules.

28. The compound of claim 1 :

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2023
From: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
To: ENZO BIOCHEM, INC.; ENZO CLINICAL LABS, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP; ENZO LIFE SCIENCES, INC.
Reel/Frame 064369/0031 →
SECURITY INTEREST Recorded Apr 3, 2023
From: ENZO LIFE SCIENCES, INC.; ENZO CLINICAL LABS, INC.; ENZO BIOCHEM, INC.; ENZO LIFE SCIENCES U.S. HOLDING CORP
To: GEMINO HEALTHCARE FINANCE, LLC D/B/A SLR HEALTHCARE ABL
Reel/Frame 063239/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2011
From: COLEMAN, JACK; RABBANI, ELAZAR; STAVRIANOPOULOS, JANNIS; PANDE, PRAVEEN
To: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.
Reel/Frame 026876/0513 →
Continuity (3)
Continuation In Part 12399393 · Mar 6, 2009
Division 10407818 · Apr 3, 2003
Related Publication 20110318788A1 · Dec 29, 2011